EDISON, N.J. -- A recent study has shown that the long-term use of PerioChip as an adjunct to a routine periodontal maintenance program in patients with periodontal disease is both safe and effective.
Routine periodontal maintenance is a therapeutic option among dentists where periodontal patients are monitored and treated on a regular interval, typically every three months. However, past research has shown that periodontal pockets can be maintained, which is considered stable; but typically do not improve over time.
The study, published in the April 2003 issue of the Journal of Periodontology, evaluated the efficacy of controlled-release delivery of chlorhexidine gluconate, (PerioChip by Dexcel Pharma), and showed a continual decrease in pocket depth over a 24-month period in patients who were seen every three months as a part of a routine periodontal maintenance program.
Periodontal disease is initiated by specific bacteria within the gingival tissues. PerioChip is a small biodegradable chip containing chlorhexidine gluconate, which is the gold-standard, broad-spectrum antimicrobial agent. PerioChip is easily inserted into the periodontal pocket around the tooth. It dissolves naturally in the pocket over seven to 10 days, killing all bacteria and inhibiting the proliferation of perio-pathogenic bacteria for an extended period of time. Patients can eat, drink, and brush their teeth as usual after treatment.
During this study, led by Dr. Aubrey Soskolne, 835 patients in private dental practices had periodontal pockets greater than or equal to 5 mm treated with PerioChip in conjunction with their routine periodontal maintenance visits. At the end of the 24-month study, 73 percent of sites improved, 58.9 percent of sites had been reduced to pocket depths of < 5mm and only 2.9% of sites had increased by greater than or equal to 2mm. Adverse events were mild to moderate in nature and resolved spontaneously without medication. Therefore, this study supports PerioChip as a safe and effective adjunct in long-term management of periodontal patients.
Source: Dexcel Pharma, Inc.
APIC Salutes 2025 Trailblazers in Infection Prevention and Control
June 18th 2025From a lifelong mentor to a rising star, the Association for Professionals in Infection Control and Epidemiology (APIC) honored leaders across the career spectrum at its 2025 Annual Conference in Phoenix, recognizing individuals who enhance patient safety through research, leadership, and daily practice.
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.
Swift Isolation Protocol Shields Chicago Children’s Hospital During 2024 Measles Surge
June 17th 2025When Chicago logged its first measles cases linked to crowded migrant shelters last spring, one pediatric hospital moved in hours—not days—to prevent the virus from crossing its threshold. Their playbook offers a ready template for the next communicable-disease crisis.
Back to Basics: Hospital Restores Catheter-Associated UTI Rates to Prepandemic Baseline
June 16th 2025A 758-bed quaternary medical center slashed catheter-associated urinary tract infections (CAUTIs) by 45% over 2 years, proving that disciplined adherence to fundamental prevention steps, not expensive add-ons, can reverse the pandemic-era spike in device-related harm.